TrialThe oncologist2025

Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer.

Li Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.